Innovative Therapeutics Abide Therapeutics focuses on first-in-class serine hydrolase inhibitors targeting CNS disorders, presenting an opportunity for partners with expertise in neurological therapeutic development or specialized chemical libraries to collaborate on innovative drug discovery initiatives.

Growing Clinical Pipeline The company's lead candidate ABX-1431 is in clinical trials for Tourette’s and neuropathic pain, signaling a need for advanced clinical trial support, regulatory consulting, and specialized medical communications to accelerate development and commercialization efforts.

Strategic Acquisitions Having been acquired by Lundbeck Group for 250 million dollars, Abide demonstrates interest in expanding its portfolio through strategic partnerships, providing opportunities for distribution, licensing, or joint ventures in neuroscience and rare neurological indications.

Research Collaborations Abide’s partnership with the Tourette Association of America highlights an openness to research collaborations and community engagement, opening avenues for advocacy, patient support programs, and early access services that can strengthen market positioning.

Emerging Market Presence With a lean team of up to 50 employees and a focus on cutting-edge biotech research, Abide offers opportunities for OEMs, technology providers, and CROs specializing in biotech infrastructure, analytical tools, or clinical services to support its growth and operational needs.